Autorenfreundlich Bücher kaufen?!
Beschreibung
This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.
Clinical Studies combined with chemotherapy and radioimmunotherapy, and DCE-MRI and immunohistochemistry correlation
Details
| Verlag | LAP LAMBERT Academic Publishing |
| Ersterscheinung | 10. Mai 2011 |
| Maße | 22 cm x 15 cm x 1.6 cm |
| Gewicht | 399 Gramm |
| Format | Softcover |
| ISBN-13 | 9783838343532 |
| Seiten | 256 |
Schlagwörter
Bekannt durch
